You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Chemiluminescent Assay and Device for Monitoring Vascular Endogenous Nitric Oxide

    SBC: BIOLUM SCIENCES LLC            Topic: 400

    Project Summary A Chemiluminescent Assay and Device for Monitoring Vascular Endogenous Nitric Oxide This STTR Phase I project aims to establish the feasibility of a novel chemiluminescent assay for the detection of nitric oxide in blood. Phase II will aim to use this assay in a point-of-care device to measure vascular endogenous nitric oxide (VeNO) from a finger-prick of blood for ultimate deploym ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. A Cloud based Application for the Joint Analysis of Multiple Big Data Types

    SBC: MathNimbus Inc            Topic: 400

    Project Summary Technology advances now enable the cost effective acquisition of Kandgt distinct data types from a common set of N bio samples where i the kth data type is represented by a data matrix with columns containing Pk measurements in N samples for k K and ii at least one of the data types is big i e Pk is much bigger than N for some k The rapid accumulation of such mult ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Activated Organophosphate Hydrolase for Coupling to Human Skin

    SBC: LYNNTECH INC.            Topic: N/A

    This Phase II STTR proposal describes an activated form of organophosphate hydrolyzing enzyme that, when dissolved in water, forms a covalent bond to skin. In Phase I, a lyophilized preparation of Organophosphate Hydrolase (OPH) from Pseudomonas diminutaretained the capability to couple to skin and to hydrolyze nerve agent surrogates when stored for months at 40¿C. Immobilized enzyme also retai ...

    STTR Phase I 2001 Department of DefenseArmy
  4. Activated Organophosphate Hydrolase for Coupling to Human Skin

    SBC: LYNNTECH INC.            Topic: N/A

    This Phase II STTR proposal describes an activated form of organophosphate hydrolyzing enzyme that, when dissolved in water, forms a covalent bond to skin. In Phase I, a lyophilized preparation of Organophosphate Hydrolase (OPH) from Pseudomonas diminutaretained the capability to couple to skin and to hydrolyze nerve agent surrogates when stored for months at 40¿C. Immobilized enzyme also retai ...

    STTR Phase II 2001 Department of DefenseArmy
  5. Activated Reactants to Reduce Fuel Cell Overpotentials

    SBC: JSJ Technologies, LLC            Topic: A10AT011

    The current produced in electrochemical galvanic cells is primarily dependent on the rate of the electrode reactions where the cell's anode is less negative, supplying less energy than thermodynamically predicted, and the cell's cathode is less positive, supplying less energy than thermodynamically predicted. Reduction of electrochemical overpotentials in electrochemical systems has been the prim ...

    STTR Phase I 2010 Department of DefenseArmy
  6. Activated Reactants to Reduce Fuel Cell Overpotentials

    SBC: JSJ Technologies, LLC            Topic: A10aT011

    he current produced in electrochemical galvanic cells is primarily dependent on the rate of the electrode reactions where the cell's anode is less negative, supplying less energy than thermodynamically predicted, and the cell's cathode is less positive, supplying less energy than thermodynamically predicted. Reduction of electrochemical overpotentials in electrochemical systems has been ...

    STTR Phase II 2012 Department of DefenseArmy
  7. ADF, novel cytokine PPAR-gamma regulator from fat cells

    SBC: GENETEX, INC.            Topic: N/A

    DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a major risk factor for diabetes mellitus (type 2; NIDDM). Fat cells secrete both diabetes promoting molecules (fatty acids; TNF-alpha) and at least one molecule that may be antidiabetic (leptin). We have partially purified a new protein (cytokine) which is also secreted by mature adipocytes, Adipocyte Diffe ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. A DIAGNOSTIC TEST TO ASSESS RISK ASSOCIATED WITH ANDROGEN THERAPY

    SBC: G AND H MEDICAL PRODUCTS INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant): The indications for androgen therapy has expanded such that today, androgens are used in both men and women, and in addition to their use in treating primary (or secondary) hypogonadism the potential benefit of increasing bone mineral density, inducing greater muscle mass and strength, enhancing sexual function, and improving mood. Androgens are also being cons ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  9. Adjustable Autonomy for Intelligent Operation of Mobile Manipulators

    SBC: Traclabs Inc.            Topic: A11aT032

    In recent years, the military has been integrating robotic systems into tasks previously performed entirely manually by soldiers. Examples include explosive ordnance disposal (EOD), surveillance and reconnaissance, urban search and rescue (USAR), chemical, biological, and nuclear (CBN) operations, and medical assistance and evacuation. A typical application is for a soldier (remote operator) to te ...

    STTR Phase I 2011 Department of DefenseArmy
  10. ADULT HUMAN PROGENITOR CELLS FOR CARDIAC REGENERATION

    SBC: KARDIA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to create new cardiac tissue using progenitor cells via engraftment would be a significant advance. However, the existing types of progenitor cells presently in Phase I clinical trials face significant limitations, including lack of evidence that the donor cells (1) produce new cardiac myocytes, versus creating benefits via neoangiogenesis or ventr ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government